查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1471964

卵巢癌藥物市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按類型、藥物類別、配銷通路和地理位置

Ovarian Cancer Drugs Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Drug Class, Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

卵巢癌藥物市場規模預計將從2022年的21億美元成長到2030年的38億美元。

卵巢癌發生率上升推動對治療選擇的需求推動市場成長

卵巢癌是女性第七大常見癌症，也是繼子宮頸癌和子宮內膜癌之後第三大常見婦科惡性腫瘤。根據世界卵巢癌聯盟的報告，每年有324,000名女性被診斷出患有卵巢癌，其中207,000人死於該疾病。此外，大多數卵巢癌患者被診斷為晚期（局部晚期或轉移性），因為沒有可用於早期檢測卵巢癌的公共衛生篩檢計劃。因此，卵巢癌發生率的上升推動了對治療選擇的需求。減瘤手術和鉑類化療相結合的一線治療是新診斷患有晚期卵巢癌的女性的標準治療方法。此外，治療新診斷卵巢癌的突破性選擇是經批准的 PARP 抑制劑、olaparib、rucaparib 和 niraparib 等治療選擇。使用 PARP 抑制劑治療晚期卵巢癌已成為改善該疾病患者臨床結果的有效治療選擇。例如，PARP 抑制劑為新診斷的疾病在對第一、第二和第三次鉑類化療完全緩解 (CR) 後提供長期療效和無惡化存活 (PFS)。因此，卵巢癌治療藥物的重大產品批准將對卵巢癌藥物市場規模產生積極影響。

因此，上述因素正在增加對卵巢癌疾病管理藥物的需求，促進市場佔有率的擴大。

卵巢癌市場趨勢

聯合藥物治療

用於卵巢癌的聯合藥物治療將在未來幾年顯著成長。此外，一些醫學研究機構正在開發一種治療卵巢癌的新型組合藥物。例如，2023 年 9 月，皇家馬斯登的研究人員宣布了新的藥物聯合療法，該療法已被證明對晚期卵巢癌患者有效。研究人員測試了低度漿液性卵巢癌（LGSOC）的聯合藥物療法，這是一種罕見的卵巢癌，對治療的反應率較差。臨床試驗「RAMP-201試驗」是針對患有LGSOC的患者，使用「avutometinib」藥物與另一種藥物「defactinib」的組合進行的。中期臨床試驗結果顯示，接受該藥物組合治療的患者中，45% 的腫瘤明顯縮小。聯合療法如此令人滿意的臨床效果，與名為「trametinib」的標靶藥物療法相比，其療效幾乎是後者的兩倍，而這種藥物在英國上市，反應率僅為 26%。此外，2024年1月，FDA宣布批准「SH-105」作為組合藥物用於治療乳癌和卵巢癌患者。這些臨床進展和產品核准是改善女性乳癌和卵巢癌藥物取得和管理的重要步驟。這些臨床進展為製造商將創新組合產品推向全球市場提供了有利可圖的機會。

卵巢癌藥物市場，依類型：

依類型分類，卵巢癌藥物市場分為上皮性卵巢癌、生殖細胞卵巢癌和間質瘤。上皮性卵巢癌細分市場在 2022 年佔據最大的卵巢癌藥物市場佔有率，預計該細分市場在預測期內複合年成長率最高，為 8.2%。

根據英國癌症研究中心的報告，上皮性卵巢癌是最常見的卵巢癌類型。例如，100 個卵巢腫瘤中約有 90 個（90%）是上皮性腫瘤。因此，快速藥品核准是治療上皮性卵巢癌的關鍵因素，從而對 2020-2030 年預測期內有影響力的細分市場成長負責。此外，患有侵襲性晚期卵巢癌的患者的治療選擇有限。例如，2022 年 11 月，美國食品藥物管理局 (FDA) 宣布批准 Elahere Nutrition, Inc. 生產的「mirvetuximab soravtansine-gynx」用於治療患有上皮性卵巢癌的成年患者。醫師建議的「mirvetuximab soravtansine-gynx」劑量為 6mg/kg，每三週一次靜脈輸注，用於患有上皮性卵巢癌的患者。此外，2024年1月，FDA宣布批准「RC88」的快速通道指定（FTD），RC88是一種間皮素標靶抗體藥物偶聯物（ADC），用於治療復發性上皮性卵巢癌患者。

競爭格局及重點企業：

禮來公司、阿斯特捷利康、葛蘭素史克、Zielab、ImmunoGen (艾伯維)、GeneTech (羅氏)、Vivesto、Allarity Therapeutics, Inc.、Aeterna Zentaris 和Luye Pharma 是卵巢癌藥物市場報告中的知名公司。這些公司專注於新技術、升級現有產品和地理擴張，以滿足全球不斷成長的消費者需求。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 重要見解
  • 市場吸引力分析

第 3 章：研究方法

第 4 章：卵巢癌藥物市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈供應商名單

第 5 章：卵巢癌藥物市場 - 主要市場動態

  • 主要市場促進因素
  • 主要市場限制
  • 主要市場機會
  • 未來的趨勢
  • 促進因素和限制因素的影響分析

第 6 章：卵巢癌藥物市場 - 全球市場分析

  • 卵巢癌藥物 - 全球市場概覽
  • 卵巢癌藥物 - 全球市場與 2031 年預測

第 7 章：卵巢癌藥物市場 - 收入分析 - 按類型，2021-2031

  • 概述
  • 上皮性卵巢癌
  • 生殖細胞卵巢癌
  • 間質瘤

第 8 章：卵巢癌藥物市場 - 收入分析 - 按藥物類別，2021-2031

  • 概述
  • PARP抑制劑
  • 抗血管新生抑制劑
  • 其他

第 9 章：卵巢癌藥物市場 - 收入分析 - 按配銷通路，2021-2031 年

  • 概述
  • 醫院藥房
  • 零售藥局
  • 其他

第 10 章：卵巢癌藥物市場 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

註 - 將為以下提到的地區/國家提供類似的分析

  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 12 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與專注

第 13 章：卵巢癌藥物市場 - 主要公司概況

  • AbbVie Inc
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Pfizer, Inc.
  • Merck and Co., Inc.
  • ImmunoGen, Inc
  • CLOVIS ONCOLOGY
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline, Plc
  • Amgen Inc

第 14 章：附錄

簡介目錄
Product Code: TIPRE00003750

The ovarian cancer drugs market size is expected to grow from US$ 2.1 billion in 2022 to US$ 3.8 billion by 2030. Factors such as the rising incidence of ovarian cancer propel the demand for therapeutic options thereby responsible for influential ovarian cancer drugs market growth.

Rising Incidence Of Ovarian Cancer Propel The Demand For Therapeutic Options Drives Market Growth

Ovarian cancer is the seventh most common cancer among women and the third most common gynecological malignancy after cervical cancer and endometrial (uterine) cancers. According to the World Ovarian Cancer Coalition report, 324,000 women are diagnosed with ovarian cancer, among which 207,000 die of the disease annually. Further, the majority of patients with ovarian cancer are diagnosed with advanced (locally advanced or metastatic) stage as there is no public health screening program available for early detection of ovarian cancer. Therefore, the rising incidence of ovarian cancer propels the demand for therapeutic options. The first-line therapy with a combination of debulking surgery and platinum-based chemotherapy is standard care for women newly diagnosed with advanced ovarian cancer. Also, the breakthrough options for the management of newly diagnosed ovarian cancer are therapeutic options such as approved PARP inhibitors, olaparib, rucaparib, and niraparib. The use of PARP inhibitors in the management of advanced ovarian cancer has emerged as an effective therapeutic option to improve clinical outcomes for patients suffering from the disease. For example, PARP inhibitors provide long-term efficacy and progression-free survival (PFS) for the newly diagnosed disease following a complete response (CR)to first, second, and third platinum-based chemotherapy. Therefore, significant product approvals for ovarian cancer treatment drugs will positively impact the ovarian cancer drugs market size.

Therefore, the aforementioned factors are increasing the demand for ovarian cancer drugs for disease management, facilitating the expansion of the market share.

Ovarian Cancer Market Trends

Combination Drug Therapy

Combination drug therapy intended for ovarian cancer will grow significantly in the coming years. Also, several medical research institutes are developing a novel combination drug to treat ovarian cancers. For example, in September 2023, Researchers at the Royal Marsden announced new drug combination therapy that proves effective for patients living with advanced ovarian cancer. The researchers tested combination drug therapy for low-grade serous ovarian cancer (LGSOC), which is a rare form of ovarian cancer that has a poor response rate to treatments. The clinical trial "RAMP-201 trial" was conducted by using the "avutometinib" drug with a combination of another drug, namely, "defactinib," for patients suffering from LGSOC. The interim clinical trial results reveal that 45% of the patients treated with the drug combination saw their tumors shrink significantly. Such satisfactory clinical results with combination therapy is almost twice as effective compared to the targeted drug therapy called "trametinib," a drug available in England that has a response rate of only 26%. Further, in January 2024, the FDA announced approval for "SH-105" for the treatment of patients with breast and ovarian cancer as a combination drug. Such clinical advancements and product approvals are important steps to improve access to and administration of drugs that will treat breast and ovarian cancer among women. Such clinical advancements present a lucrative opportunity for the manufacturers to bring innovative combination products into the global market.

Ovarian Cancer Drugs Market, by Type:

By type, the ovarian cancer drugs market is segmented into epithelial ovarian cancer, germ cell ovarian cancer, and stromal tumors. The epithelial ovarian cancer segment held the largest ovarian cancer drugs market share in 2022 and the same segment is anticipated to register the highest CAGR of 8.2% during the forecast period.

According to the Cancer Research UK report, epithelial ovarian cancer is the most common type of ovarian cancer. For example, about 90 out of 100 tumors of the ovary (90%) are epithelial. Therefore, fast drug product approvals is a key factor in treating epithelial ovarian cancer thereby responsible for influential segment growth for the forecast period 2020-2030. Also, patients with aggressive, late-stage ovarian cancer have limited treatment options. For instance, in November 2022, the Food and Drug Administration (FDA) announced approval for "mirvetuximab soravtansine-gynx," manufactured by Elahere ImmunoGen, Inc. for adult patients suffering from epithelial ovarian cancer. The "mirvetuximab soravtansine-gynx" is a recommended dose by the physician of 6mg/kg administered once every three weeks as an IV infusion for epithelial ovarian cancer suffering patients. Additionally, in January 2024, the FDA announced approval for fast-track designation (FTD) for "RC88," a mesothelin-targeting antibody-drug conjugate (ADC) for the treatment of patients with recurrent epithelial ovarian cancer.

Competitive Landscape and Key Companies:

Elli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris, and Luye Pharma are the prominent companies in the ovarian cancer drugs market report. These companies focus on new technologies, upgrading existing products, and geographic expansions to meet the growing consumer demand worldwide.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Ovarian Cancer Drugs Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Ovarian Cancer Drugs Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Ovarian Cancer Drugs Market - Global Market Analysis

  • 6.1 Ovarian Cancer Drugs - Global Market Overview
  • 6.2 Ovarian Cancer Drugs - Global Market and Forecast to 2031

7. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million) - By Type, 2021-2031

  • 7.1 Overview
  • 7.2 Epithelial Ovarian Cancer
  • 7.3 Germ Cell Ovarian Cancer
  • 7.4 Stromal Tumors

8. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million) - By Drug Class, 2021-2031

  • 8.1 Overview
  • 8.2 PARP Inhibitors
  • 8.3 Anti-Angiogenesis Inhibitors
  • 8.4 Others

9. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Others

10. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Ovarian Cancer Drugs Market Overview
    • 10.1.2 North America Ovarian Cancer Drugs Market Revenue and Forecasts to 2031
    • 10.1.3 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Type
    • 10.1.4 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Drug Class
    • 10.1.5 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 10.1.6 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Ovarian Cancer Drugs Market
        • 10.1.6.1.1 United States Ovarian Cancer Drugs Market, by Type
        • 10.1.6.1.2 United States Ovarian Cancer Drugs Market, by Drug Class
        • 10.1.6.1.3 United States Ovarian Cancer Drugs Market, by Distribution Channel
      • 10.1.6.2 Canada Ovarian Cancer Drugs Market
        • 10.1.6.2.1 Canada Ovarian Cancer Drugs Market, by Type
        • 10.1.6.2.2 Canada Ovarian Cancer Drugs Market, by Drug Class
        • 10.1.6.2.3 Canada Ovarian Cancer Drugs Market, by Distribution Channel
      • 10.1.6.3 Mexico Ovarian Cancer Drugs Market
        • 10.1.6.3.1 Mexico Ovarian Cancer Drugs Market, by Type
        • 10.1.6.3.2 Mexico Ovarian Cancer Drugs Market, by Drug Class
        • 10.1.6.3.3 Mexico Ovarian Cancer Drugs Market, by Distribution Channel

Note - Similar analysis would be provided for below mentioned regions/countries

  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Ovarian Cancer Drugs Market - Key Company Profiles

  • 13.1 AbbVie Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 13.2 AstraZeneca
  • 13.3 F. Hoffmann-La Roche Ltd
  • 13.4 Pfizer, Inc.
  • 13.5 Merck and Co., Inc.
  • 13.6 ImmunoGen, Inc
  • 13.7 CLOVIS ONCOLOGY
  • 13.8 Boehringer Ingelheim International GmbH
  • 13.9 GlaxoSmithKline, Plc
  • 13.10 Amgen Inc

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud